These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23412014)

  • 1. QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.
    Kaye AD; Volpi-Abadie J; Bensler JM; Kaye AM; Diaz JH
    J Anesth; 2013 Aug; 27(4):575-87. PubMed ID: 23412014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of QT interval duration in patients with wide QRS].
    Guinand A; Namdar M; Burri H; Shah D
    Rev Med Suisse; 2016 May; 12(520):1049-53. PubMed ID: 27424344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QT interval measurement in ventricular pacing: Implications for assessment of drug effects and pro-arrhythmia risk.
    Schurr JW; Grewal PK; Fan R; Rashba E
    J Electrocardiol; 2022; 70():13-18. PubMed ID: 34826635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
    Drici MD; Clément N
    Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premature atrial contraction induces torsades de pointes in a patient of Takotsubo cardiomyopathy with QT prolongation.
    Kawano H; Matsumoto Y; Arakawa S; Satoh O; Hayano M
    Intern Med; 2010; 49(16):1767-73. PubMed ID: 20720356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes.
    Madias C; Fitzgibbons TP; Alsheikh-Ali AA; Bouchard JL; Kalsmith B; Garlitski AC; Tighe DA; Estes NA; Aurigemma GP; Link MS
    Heart Rhythm; 2011 Apr; 8(4):555-61. PubMed ID: 21146632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug induced QT prolongation].
    Altmann D; Eggmann U; Ammann P
    Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Arrest Following Torsades de Pointes Caused by Hypokalemia and Catecholamines in a Patient with Congenital Long QT Syndrome Type 1 After Surgical Aortic Valve Replacement: A Case Report.
    Kitaura A; Nakao S; Yuasa H; Tsukimoto S; Nakajima Y
    Am J Case Rep; 2022 Dec; 23():e938609. PubMed ID: 36523136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
    Thomas SH; Behr ER
    Br J Clin Pharmacol; 2016 Mar; 81(3):420-7. PubMed ID: 26183037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Torsades de pointes related to transient marked QT prolongation following successful emergent percutaneous coronary intervention for acute coronary syndrome.
    Kawabata M; Hirao K; Takeshi S; Sakurai K; Inagaki H; Hachiya H; Isobe M
    J Electrocardiol; 2008; 41(2):117-22. PubMed ID: 18328336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case illustrations of long QT syndrome.
    Razakjr OA; Tiong YW; Chong SS; Devinder S
    Am Heart Hosp J; 2010; 8(1):58-62. PubMed ID: 21194054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
    Gupta A; Lawrence AT; Krishnan K; Kavinsky CJ; Trohman RG
    Am Heart J; 2007 Jun; 153(6):891-9. PubMed ID: 17540188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
    Shah RR
    Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-loop, clockwise QT-RR hysteresis immediately before the onset of torsades de pointes in type 2 long QT syndrome.
    Nakaji G; Fujiwara M; Fukata M; Yasuda S; Odashiro K; Maruyama T; Akashi K
    J Electrocardiol; 2010; 43(3):261-3. PubMed ID: 20079908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.
    Uvelin A; Pejaković J; Mijatović V
    J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocardial arrhythmogenic mechanisms of torsades de pointes in patients with the congenital long QT syndrome.
    Chinushi M; Furushima H; Hosaka Y; Komura S; Sato A; Iijima K; Aizawa Y
    Intern Med; 2011; 50(16):1695-702. PubMed ID: 21841328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.